Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
This article was originally published in PharmAsia News
Executive Summary
The acquisition of Solvay's pharmaceutical unit, completed in February, gave Abbott a substantial branded generics business and strengthened its international presence. Now the company is looking to build on those assets with an enhanced emerging market strategy
You may also be interested in...
Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States
Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia
Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States
Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia
Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News
Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.